½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1445728

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Microneedle Drug Delivery Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 2024³â 30¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â±îÁö 41¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£(2024-2029³â) µ¿¾È 6.83%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ - ½ÃÀå

COVID-19´Â ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. Á¤ºÎÀÇ ºÀ¼â Á¶Ä¡¿Í º´¿ø ¹× Áø·á¼Ò Æó¼â·Î ÀÎÇØ ¸¸¼º ¹× »ýÈ°½À°üº´ ȯÀڵ鿡 ´ëÇÑ ¼­ºñ½º°¡ ÁߴܵǾú°í, COVID-19 °¨¿°ÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ±â¾÷ ¹× ±â°üÀº Àü¿°º´ ±â°£ µ¿¾È ¾à¹°À» Àü´ÞÇϱâ À§ÇØ ¼Õ°¡¶ô ³¡ Å©±âÀÇ ÇǺΠÆÐÄ¡ °³¹ß¿¡ ÁýÁßÇÏ°Ô µÇ¾ú½À´Ï´Ù. °³¹ßÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, ACS°¡ 2020³â 5¿ù¿¡ ¹ßÇ¥ÇÑ ±â»ç¿¡ µû¸£¸é, ÇÇÃ÷¹ö±× ´ëÇÐ ¸ÞµðÄà ¼¾ÅÍ¿Í ÇÇÃ÷¹ö±× ´ëÇÐ ¿¬±¸ÁøÀº 400°³ÀÇ ¹Ì¼¼ÇÑ ¹Ù´ÃÀ» ÁÖÀÔÇÏ´Â ¼Õ°¡¶ô ³¡ Å©±âÀÇ ÆÐÄ¡ÀÎ ¸¶ÀÌÅ©·Î´Ïµé ¾î·¹ÀÌ(MNA)¸¦ °³¹ßÇÏ·Á°í ½ÃµµÇß´Ù°í ÇÕ´Ï´Ù. ¸é¿ª¹ÝÀÀÀÌ °¡Àå °­·ÂÇÑ ÇǺο¡ ´Ü¹éÁú Á¶°¢À» ½ºÆÄÀÌÅ©ÇÏ´Â ¹æ½ÄÀÔ´Ï´Ù. µû¶ó¼­ COVID-19 °¨¿° ¹é½Å Á¢Á¾À» À§ÇÑ ¸¶ÀÌÅ©·Î´Ïµé »ç¿ëÀº ÆÒµ¥¹Í ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ¶ÇÇÑ, µÎ ȸ»çÀÇ ÃÊÁ¡Àº ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡¿Í ¾à¹°Àü´Þ ½Ã½ºÅÛ °³¹ß·Î ¿Å°Ü°¡°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 10¿ù Tapemark´Â 10X Technology¿Í Á¦ÈÞÇÏ¿© ¸¶ÀÌÅ©·Î´Ïµé ±â¼úÀ» »ç¿ëÇÏ¿© °æÇÇ ÆÐÄ¡¸¦ ÅëÇØ ´Ù¾çÇÑ ¾à¹°À» Åõ¿©ÇÏ´Â MicroDermÀ» »ó¿ëÈ­Çß½À´Ï´Ù. ÆÐÄ¡ÀÇ ÀÛÀº ¹Ì¼¼ ¹Ù´ÃÀº ÇÇÇÏ ÁÖ»ç ¹Ù´Ã¿¡ ºñÇØ ºÒÆí ÇÔÀ̳ª ºÒÆí ÇÔÀ» À¯¹ßÇÏÁö ¾Ê°í ¾à¹°ÀÌ Ç÷·ù¿¡ µµ´Þ ÇÒ ¼öÀÖÀ»¸¸Å­ ÃæºÐÈ÷ ±í¼÷ÀÌ ÇǺθ¦ °üÅëÇÕ´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¹ßÀüÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼º Áúȯ ¹× »ýÈ°½À°üº´ÀÇ Áõ°¡, ¹«Åë ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¿¬±¸ Áõ°¡, ±â¼ú ¹ßÀü, ±âÁ¸ ÇÇÇÏ Áֻ縦 ´ëüÇÒ ¼ö ÀÖ´Â ¾ÈÀüÇÑ ´ë¾È¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°èÀûÀ¸·Î ¸¸¼º ÁúȯÀÇ À¯º´·ü°ú ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÌ°í Áøº¸µÈ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 1¿ù¿¡ ¹ßÇ¥µÈ BHF À×±Û·£µå ÆÑÆ® ½ÃÆ®¿¡ µû¸£¸é 2021³â ¿µ±¹¿¡¼­ ¾à 640¸¸ ¸íÀÌ ½ÉÇ÷°ü ÁúȯÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ BHF°¡ ¹ßÇ¥ÇÑ 2022³â Åë°è¿¡ µû¸£¸é ¾à 740¸¸ ¸íÀÌ ½ÉÀåÀ» °¡Áö°í »ì°Ô µÉ °ÍÀ̶ó°í ÇÕ´Ï´Ù. µû¶ó¼­ ½ÉÇ÷°ü ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ ¼ö°¡ ¸¹±â ¶§¹®¿¡ ¾à¹° ¹æÃâ Á¦¾î ¶Ç´Â ¼­¹æÇü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, IDF°¡ ¹ßÇ¥ÇÑ 2022³â Åë°è¿¡ µû¸£¸é 2021³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î ¾à 5¾ï 3,700¸¸ ¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ÀÌ ¼ýÀÚ´Â 2030³â±îÁö 6¾ï 4,300¸¸ ¸í, 2045³â±îÁö 7¾ï 8,400¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ ´ç´¢º´ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ħ½À¼ºÀ» ÃÖ¼ÒÈ­ÇÏ°í ÅëÁõÀÌ ¾ø´Â ¹æ½ÄÀ¸·Î ÇǺΠ°¢ÁúÃþÀ» ÅëÇØ Àν¶¸°À» Àü´ÞÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î´Ïµé ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» È®´ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ°ú °ü·ÃµÈ ¿¬±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¾à¹°Àü´Þ, ¹é½Å Çü¼º ¶Ç´Â ¸¶ÀÌÅ©·Î´Ïµé ½Ã½ºÅÛÀ» ÅëÇÑ ´Ù¾çÇÑ Áúº´ Ä¡·á¿¡¼­ ¸¶ÀÌÅ©·Î´Ïµé äÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¶ÇÇÑ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 10¿ù Journal of Pharmaceutical Innovation¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é, ¹Ì¼¼ÀüÀÚ±â°è½Ã½ºÅÛ(MEMS) ±â¹Ý ¸¶ÀÌÅ©·Î´ÏµéÀº ÇǺΠÅõ°ú¼ºÀ» Çâ»ó½ÃÅ°´Â Çõ½ÅÀûÀÎ ¾à¹°Àü´Þ ¹æ¹ýÀÎ °ÍÀ¸·Î °üÂûµÇ¾ú½À´Ï´Ù. ÇǺΠ³»¿¡ ¹Ì¼¼ÇÑ ±â°øÀ» Çü¼ºÇÏ¿© ¼öµ¿Àû ¾à¹° È®»ê°ú ÇǺΠ¹Ì¼¼ ¼øȯÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ Çö»óÀº ¾à¹°ÀÇ È¿°úÀûÀΠħÅõ¸¦ µ½½À´Ï´Ù. °á°úÀûÀ¸·Î ¸¶ÀÌÅ©·Î´ÏµéÀÇ ÀåÁ¡Àº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ¸¶ÀÌÅ©·Î´Ïµé Á¦Ç° °³¹ß ¹× Ãâ½Ã Áõ°¡¿¡ ´ëÇÑ ±â¾÷ È°µ¿ÀÇ Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 1¿ù Á¶ÀÚ³ëÁ¦¾àÀº ÀÚ»çÀÇ °æÇÇ¿ë ¸¶ÀÌÅ©·Î´Ïµé ½Ã½ºÅÛ¿¡¼­ »ý»êµÈ 3°¡ µ¶°¨ ¹é½ÅÀÌ ±ÙÀ°¿¡ ÁÖ»çÇÑ °Í°ú µ¿ÀÏÇÑ ¿ë·®ÀÇ ¹é½ÅÀ» °í¿ë·®À¸·Î ÁÖ»çÇÑ °Í°ú µ¿µîÇÑ È¿°ú¸¦ º¸ÀÔ´Ï´Ù´Â ÀÓ»ó µ¥ÀÌÅ͸¦ ¹ßÇ¥Çß½À´Ï´Ù.

µû¶ó¼­, ¸¸¼ºÁúȯ ¹× »ýÈ°½À°üº´ÀÇ ³ôÀº ºÎ´ã, ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Ã¤Åà Áõ°¡¿Í °°Àº ¾Õ¼­ ¾ð±ÞÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª Á¦ÇÑµÈ ¼öÀÇ ½ÂÀÎµÈ Á¦Ç°°ú ¸¶ÀÌÅ©·Î´Ïµé °ü·Ã ÇÕº´Áõ ¹× À§ÇèÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå µ¿Çâ

¹é½Å Àü´Þ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ½ÃÀå Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

¹é½Å Àü´Þ ºÎ¹®Àº ÀÎÇ÷翣ÀÚ ¹× ¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ È®»ê°ú ¸¶ÀÌÅ©·Î´Ïµé ¹é½Å ¿¬±¸ ¹× °³¹ß¿¡ ÁÖ·ÂÇÏ´Â ÁÖ¿ä ±â¾÷ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, Àεµ ±¹¸³Áúº´ÅëÁ¦¼¾ÅÍ(NCDC)ÀÇ 2022³â º¸°í¼­¿¡ µû¸£¸é, 2022³â 10¿ù 31ÀÏ ±âÁØ Àεµ¿¡¼­ º¸°íµÈ °èÀý¼º µ¶°¨(H1N1) »ç·Ê´Â ¾à 12,563°ÇÀÎ ¹Ý¸é, 2021³â ÀüüÀûÀ¸·Î´Â 778°Ç¿¡ ºÒ°úÇß½À´Ï´Ù. ÀÌ´Â ¸¶ÀÌÅ©·Î´Ïµé ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÀÚ±ØÇÏ¿© ÇØ´ç ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ 2022³â 12 ¿ù¿¡ ¹ßÇ¥ µÈ ±â»ç¿¡ µû¸£¸é ¸Å³â µ¶°¨ À¯ÇàÀº ¸ðµç Àα¸¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖÁö¸¸ 2 ¼¼ ¹Ì¸¸ÀÇ ¾î¸°ÀÌ, 65 ¼¼ ÀÌ»óÀÇ ¼ºÀÎ, ¸¸¼º Áúȯ ¹× ¸é¿ª·ÂÀÌ ÀúÇÏ µÈ »ç¶÷µéÀÌ °¡Àå ³ôÀº À§Çè¿¡ óÇØ ÀÖ´Ù°íÇÕ´Ï´Ù. ÇÕº´Áõ. ¿¬°£ ¹ßº´·üÀº ¼ºÀÎÀÇ °æ¿ì 5-10%, ¼Ò¾ÆÀÇ °æ¿ì 20-30%·Î ÃßÁ¤µË´Ï´Ù. µû¶ó¼­ µ¶°¨ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ µ¶°¨ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ¿¹Ãø ±â°£ µ¿¾È ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ 2021³â 4¿ù Micromachines¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é, 50-900m ±æÀÌÀÇ ¹Ù´Ã·Î È¿À²ÀûÀ¸·Î ¿¹¹æÁ¢Á¾À» ÇÒ ¼ö Àֱ⠶§¹®¿¡ ¸¶ÀÌÅ©·Î´Ïµé ¹é½Å Á¢Á¾Àº ´Ù¾çÇÑ ¹ÙÀÌ·¯½º ¹× ¼¼±Õ °¨¿°¿¡ ´ëÇØ ÇöÀúÇÑ ¸é¿ª¹ÝÀÀÀ» °¡Á®¿À´Â °ÍÀ¸·Î °üÂûµÇ¾ú½À´Ï´Ù. °üÂûµÇ°í ÀÖ½À´Ï´Ù. ¶û°Ô¸£Çѽº ¼¼Æ÷¿Í ¼öÁö»ó ¼¼Æ÷°¡ ¸¹Àº Ç¥ÇÇ¿Í ÁøÇÇ ºÎÀ§¿¡ ¹é½ÅÀ» Åõ¿©ÇÕ´Ï´Ù. ¶ÇÇÑ, °°Àº ¼Ò½ÄÅë¿¡ µû¸£¸é, ¼­¹æ¼º Æú¸®¸Ó·Î ¸¸µé¾îÁö°Å³ª ¹Ì¸³ÀÚ ¶Ç´Â ³ª³ëÀÔÀÚ¿Í ÅëÇÕµÈ ¸¶ÀÌÅ©·Î´ÏµéÀ» »ç¿ëÇÏ¸é ¿©·¯ Â÷·ÊÀÇ ¹é½Å Á¢Á¾ÀÌ ÇÊ¿äÇÏÁö ¾ÊÀ» ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ¸¹Àº ÀåÁ¡À» °¡Áö°í Àֱ⠶§¹®¿¡ ¹ÙÀÌ·¯½º ¹× ¹ÚÅ׸®¾Æ °¨¿°¿¡ ´ëÇÑ ¹é½ÅÀ» ¸¸µå´Â µ¥ »ç¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ±â´ëÇÒ ¼ö ÀÖ´Â ºÎºÐÀÔ´Ï´Ù.

¶ÇÇÑ, ½Å»ý ±â¾÷µéÀÌ ÇÕº´ ¹× Á¦ÈÞ¿Í °°Àº ´Ù¾çÇÑ ºñÁî´Ï½º Àü·«À» äÅÃÇÏ´Â µ¥ ÁÖ·ÂÇÏ°í ÀÖÀ¸¸ç, ¹é½Å Ãâ½Ã ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 10¿ù MIMIX ¼­¹æÇü Çdz» ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡¸¦ °³¹ßÇÏ´Â ¹ÙÀÌ¿ÀÅ×Å© ½ºÅ¸Æ®¾÷ÀÎ Vaxess Technologies´Â 3,600Æò¹æÇÇÆ® ±Ô¸ðÀÇ ÆÄÀÏ·µ GMP(Good Manufacturing Practice) Á¦Á¶ ½Ã¼³À» °³¼ÒÇß½À´Ï´Ù. ¶ÇÇÑ 2021³â 6¿ù Microdermics, Inc.´Â »õ·Î¿î ¸¶ÀÌÅ©·Î´Ïµé µ¶°¨ ¹é½Å ¹× ¹ÙÀÌ¿À¼¾½Ì Ç÷§ÆûÀÇ »ó¿ëÈ­¸¦ À§ÇÑ Àü·«Àû ÀÚ¹®°ú °Å·¡ ÇÁ·Î¼¼½º¸¦ ÁÖµµÇϱâ À§ÇØ ¼¼°èÀûÀÎ »ý¸í°úÇÐ ÀÚ¹® ȸ»çÀÎ Novateur Ventures¿Í ÇÕº´Çß½À´Ï´Ù. Novateur Ventures¿Í ÇÕº´Çß½À´Ï´Ù.

°¨¿°º´ ȯÀÚ ¼ö Áõ°¡, ¹é½Å Á¦Á¶¿¡ ¸¶ÀÌÅ©·Î´Ïµé »ç¿ë Áõ°¡, ±â¾÷ È°µ¿ ¹× ¹é½Å Ãâ½Ã ¼ö Áõ°¡ µîÀ¸·Î ÀÎÇØ ÇØ´ç ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

ºÏ¹Ì Áö¿ª¿¡¼­´Â ¸¸¼ºÁúȯ, ÇǺÎÁúȯ, °¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÌ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¶ÀÌÅ©·Î´Ïµé Á¦Á¶¿¡ ÀÖ¾î ÷´Ü ±â¼ú°ú ½Ã½ºÅÛÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯÀÇ Áõ°¡´Â ÀÌ Áö¿ª¿¡¼­ ¹Ì¼¼Ä§ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ³úÁ¾¾çÇùȸ°¡ ¹ßÇ¥ÇÑ 2022³â Åë°è¿¡ µû¸£¸é 2022³â¿¡´Â ¹Ì±¹¿¡¼­ ¾à 88,970¸íÀÌ ¿ø¹ß¼º ³úÁ¾¾ç Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, °°Àº ÀÚ·á¿¡ µû¸£¸é ¾à 4,170¸íÀÇ ½Å±Ô ȯÀÚ°¡ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2022³â¿¡´Â ¼Ò¾Æ ³úÁ¾¾ç 1°Ç, û¼Ò³â ¹× ÀþÀº ¼ºÀÎ ³úÁ¾¾ç 12,072°ÇÀÌ »õ·Î Áø´ÜµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ AHAÀÇ Åë°è¿¡ µû¸£¸é, ¹Ì±¹ ¼ºÀÎ 1¾ï 3,000¸¸ ¸í ÀÌ»óÀÌ 6¿ù±îÁö ¾î¶² Á¾·ùÀÇ ½ÉÀå ÁúȯÀ» ¾ÎÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2021. µû¶ó¼­ ½ÉÀ庴°ú ³úÁ¾¾çÀ» ¾Î°íÀÖ´Â »ç¶÷µéÀÇ ¼ö°¡ ¸¹±â ¶§¹®¿¡ ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ ¼ö ÀÖÀ¸¸çÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, Center for Health ProtectionÀÌ 2022³â 12¿ù¿¡ ¹ßÇ¥ÇÑ ±â»ç¿¡ µû¸£¸é, 2022³â 10¿ù 1ÀϺÎÅÍ 2022³â 11¿ù 26ÀϱîÁö ¹Ì±¹ÀÇ µ¶°¨À¸·Î ÀÎÇÑ ÀÔ¿øÀ²Àº 100,000¸í´ç 16.6¸íÀ̾ú½À´Ï´Ù. Àα¸ÀÇ µ¶°¨ ȯÀÚ Áõ°¡·Î ÀÎÇØ ºñÈ°¼ºÈ­ µÈ ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½º·Î ÄÚÆà µÈ ¸¶ÀÌÅ©·Î´Ïµé¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ´Ü´ÜÇÑ °¢ÁúÃþÀÇ ÇǺΠÀ庮À» ÅëÇØ Ç׿øÈ­¹°À» Àü´ÞÇÏ¿© ¹æ¾î ¸é¿ªÀ» À¯¹ßÇÏ°í ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÌ ½Å»ý ±â¾÷Àº ¿¹Ãø ±â°£ µ¿¾È ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â Çù¾÷, ÆÄÆ®³Ê½Ê ¹× °è¾à°ú °°Àº ´Ù¾çÇÑ Àü·«Àû À̴ϼÅƼºê¸¦ äÅÃÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¸µÅ¬½º ½´¹ÖŬ½º´Â 2021³â 12¿ù¿¡ 1,800°³ÀÇ ¸¶ÀÌÅ©·Î´ÏµéÀÌ ÇǺΠ±í¼÷ÀÌ À¯È¿ ¼ººÐÀ» Á÷Á¢ Àü´ÞÇÏ´Â Çõ½ÅÀûÀÎ ±â¼úÀ» Àû¿ëÇÑ ÀÚ°¡ ¿ëÇؼº ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ÆÐÄ¡´Â À¯È¿¼ººÐÀ» ÇǺΠÁøÇÇÃþÀ¸·Î ÀÚ°¡ ¿ëÇؽÃÄÑ ÀÛÀº ÁÖ¸§°ú ÀÜÁÖ¸§À» °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ¶ÇÇÑ 2021³â 6¿ù Æĸ¶Å׸£¿Í TSRLÀº ¸¶ÀÌÅ©·Î´Ïµé ¾î·¹ÀÌ ÆÐÄ¡ Á¦ÀÛ¿¡ Çù·ÂÇÏ´Â °øµ¿ °³¹ß °è¾àÀ» ü°áÇÑ ¹Ù ÀÖ½À´Ï´Ù.

µû¶ó¼­ Á¶»ç ´ë»ó ½ÃÀåÀº ¸¸¼º Áúȯ ¹× °¨¿°¼º ÁúȯÀ» ¾Î°í ÀÖ´Â Àα¸°¡ ¸¹°í, ±â¾÷ È°µ¿°ú ½ÅÁ¦Ç° Ãâ½Ã°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ¸î ³â µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ »ê¾÷ °³¿ä

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº ¼¼ºÐÈ­µÇ¾î ÀÖ°í °æÀïÀÌ Ä¡¿­ÇÏ¸ç ¿©·¯ ÁÖ¿ä ±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ½ÃÀå Á¡À¯À² Ãø¸é¿¡¼­ ÇöÀç ¸î¸î ´ë±â¾÷ÀÌ ½ÃÀåÀ» µ¶Á¡ÇÏ°í ÀÖ½À´Ï´Ù. ÇöÀç ½ÃÀåÀ» µ¶Á¡ÇÏ°í ÀÖ´Â ±â¾÷À¸·Î´Â 3M Company, Becton, Dickinson and Company, Raphas, Nanopass Technologies, Corium Inc. AS, nanoBioSciences LLC, Micropoint Technologies, LTS Lohmann Therapie-Systeme AG µîÀÌ ÀÖ½À´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½ÄÀÇ ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»ç °¡Á¤°ú ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼ºÁúȯÀ̳ª »ýÈ°½À°üº´ ÀÌȯÀ² Áõ°¡
    • ¹«Åë ¾à¹°Àü´Þ°ú ±â¼ú Áøº¸¿¡ °üÇÑ Á¶»ç Áõ°¡
    • ±âÁ¸ ÇÇÇÏÁֻ縦 ´ëüÇÏ´Â ´õ ¾ÈÀüÇÑ ´ëüǰ¿¡ ´ëÇÑ ¼ö¿ä »ó½Â
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÇÑÁ¤µÈ ¼öÀÇ ½ÂÀÎµÈ Á¦Ç°°ú ¸¶ÀÌÅ©·Î´Ïµé °ü·Ã ÇÕº´Áõ/¸®½ºÅ©
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ´ëü Á¦Ç°ÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • Á¦Ç° À¯Çü
    • °íü
    • Áß°ø
    • ÄÚÆÃÁ¦
    • ¿ëÇؼº
  • ¿ëµµ
    • ¾à¹°Àü´Þ
    • ¹é½ÅÀü´Þ
    • ÇǺΰú
    • ±âŸ ¿ëµµ
  • Áö¿ª
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¼¼°è ±âŸ Áö¿ª

Á¦6Àå °æÀï »óȲ

  • ±â¾÷ °³¿ä
    • Candela Corporation
    • Becton, Dickinson and Company
    • Raphas Co. Ltd.
    • Nanopass Technologies
    • Corium Inc.
    • Nitto Denko Corporation
    • Dermaroller GmbH
    • nanoBioSciences LLC
    • Micropoint Technologies
    • LTS Lohmann Therapie-Systeme AG

Á¦7Àå ½ÃÀå ±âȸ¿Í ÇâÈÄ µ¿Çâ

ksm 24.03.18

The Microneedle Drug Delivery Systems Market size is estimated at USD 3 billion in 2024, and is expected to reach USD 4.18 billion by 2029, growing at a CAGR of 6.83% during the forecast period (2024-2029).

Microneedle Drug Delivery Systems - Market

COVID-19 impacted the growth of the microneedle drug delivery market. The lockdown measures imposed by the government and the shutdown of hospitals and clinics resulted in disrupted services for patients suffering from chronic and lifestyle-related diseases. The rising COVID-19 cases increased the focus of companies and institutions to develop fingertip-sized skin patches for the delivery of drugs during the pandemic. For instance, according to an article published by ACS, in May 2020, the researchers at the University of Pittsburgh Medical Center and the University of Pittsburgh tried to develop a microneedle array (MNA), a fingertip-sized patch with 400 microscopic needles that inject spiked protein fragments into the skin, where an immune response is most potent. Thus, the use of microneedles for COVID-19 vaccination impacted the market's growth during the pandemic. Moreover, the focus of the companies is shifting toward developing microneedle patches and drug delivery systems. For instance, in October 2021, Tapemark partnered with 10X Technology to commercialize MicroDerm, which uses microneedle technology to deliver a wide range of drugs via transdermal patches. The patch's tiny microneedles penetrate the skin just deep enough for the medication to reach the bloodstream without causing discomfort or inconvenience as compared to hypodermic needles. Thus, such developments are expected to increase the market's growth over the forecast period.

The growth of the market is being driven by things like the growing number of chronic diseases and lifestyle-related disorders, more research on painless drug delivery, advances in technology, and the growing demand for a safer alternative to traditional hypodermic injections.

The increasing prevalence and burden of chronic diseases around the world are driving the demand for effective and advanced drug delivery systems, which is the key factor driving market growth. For instance, according to the BHF England Factsheet, published in January 2022, about 6.4 million people were living with cardiovascular diseases in England in 2021. Also, as per the 2022 statistics published by the BHF, around 7.4 million people will be living with heart and circulatory diseases in the United Kingdom in 2021. So, the high number of people with cardiovascular diseases drives up the demand for controlled or slow drug release, which is expected to drive market growth over the next few years.

Additionally, according to 2022 statistics published by the IDF, about 537 million people worldwide were suffering from diabetes in 2021, and this number is projected to reach 643 million and 784 million by 2030 and 2045, respectively. Thus, the expected increase in the diabetic population increases the demand for microneedle technology to deliver insulin through the stratum corneum of the skin in a minimally invasive and painless way. This is anticipated to augment market growth over the forecast period.

Furthermore, the rising research studies related to microneedle drug delivery are expected to raise its adoption during drug delivery, vaccine formation, or the treatment of various diseases through microneedle systems. This is also contributing to market growth. For instance, according to an article published by the Journal of Pharmaceutical Innovation in October 2021, it has been observed that microelectromechanical system (MEMS)-based microneedles are an innovative way of drug delivery that increases the permeability of the skin. It creates microscopic pores within the skin, allowing for passive drug diffusion and dermal microcirculation. This phenomenon aids in the effective permeation of drugs. As a result, the benefits of microneedles are expected to drive market growth over the forecast period.

Moreover, the rising company activities in developing microneedle products and increasing product launches are also contributing to the market growth. For example, in January 2022, Zosano Pharma announced that clinical data showed that a trivalent influenza vaccine made for its transdermal microneedle system was just as effective as a higher dose of the same vaccine injected into the muscle.

Therefore, owing to the aforementioned factors, such as the high burden of chronic and lifestyle-related disorders and the increasing adoption of microneedle drug delivery systems, the studied market is expected to grow over the forecast period. However, the limited number of approved products, as well as the complications or risks associated with microneedles, are likely to stymie market growth over the forecast period.

Microneedle Drug Delivery Systems Market Trends

Vaccine Delivery Segment is Expected to Hold a Significant Market Share Over the Forecast Period

The vaccine delivery segment is expected to witness significant growth in the microneedle drug delivery market over the forecast period owing to factors such as the rising prevalence of influenza and viral infections as well as the key players focusing on research and development of microneedle vaccines. For instance, according to the 2022 report of the National Center for Disease Control (NCDC) of India, as of October 31, 2022, about 12,563 cases of seasonal influenza (H1N1) were reported in India, compared to just 778 cases in overall 2021. This is also expected to fuel demand for microneedle vaccines, thereby bolstering segment growth. Also, according to an article published in December 2022, yearly influenza epidemics can affect all populations, but children younger than the age of 2, adults older than 65, as well as people with chronic medical conditions or weakened immune systems, bear the highest risk of complications. The annual attack rate is estimated at 5-10% in adults and 20-30% in children. Thus, the increasing burden of influenza raises the demand for effective influenza vaccines, which in turn is anticipated to fuel segment growth over the forecast period.

Additionally, as per an article published in Micromachines in April 2021, it has been observed that the microneedle vaccinations provide a significant immune response against a variety of viral and bacterial infections, as the needles ranging from 50 to 900 m in length can efficiently deliver the vaccine to the epidermis and the dermis region, which contain many Langerhans and dendritic cells. In addition, as per the same source, the use of microneedles made from sustained-release polymers or integrated with microparticles or nanoparticles may eliminate the requirement for multiple vaccinations. Because microneedles drug delivery systems have so many benefits, they are likely to be used to make vaccines against viral and bacterial infections. This is expected to help the segment grow.

Furthermore, the rising company's focus on adopting various business strategies such as mergers, collaboration, and others, as well as the increasing number of vaccine launches, are also expected to boost segment growth over the forecast period. For instance, in October 2021, Vaxess Technologies, a biotechnology startup developing the MIMIX sustained-release intradermal microneedle patch, opened its 3,600-square-foot pilot GMP (good manufacturing practices) manufacturing facility. Also, in June 2021, Microdermics, Inc. merged with Novateur Ventures, a well-known global life sciences advisory firm, in order to provide strategic advice and lead the transaction process for the commercialization of a new microneedle flu vaccine and biosensing platform.

Because of things like the high number of people with infectious diseases, the growing use of microneedles in making vaccines, and the increasing number of company activities and vaccine launches, the studied segment is expected to grow over the forecast period.

North America is Expected to Have the Significant Market Share Over the Forecast Period

North America is expected to witness significant growth in the microneedle drug delivery systems market over the forecast period owing to factors such as the rising prevalence of chronic diseases, skin diseases, and infectious diseases; growing technological advancement in drug delivery systems; increasing adoption of highly advanced techniques and systems in the fabrication of microneedles; and the technological advancements made in microneedle drug delivery. People are also very aware that new microneedle drug delivery systems are on the market, which helps to explain why the market is growing so quickly in the region.

The rising burden of chronic diseases is the key factor driving the demand for microneedle drug delivery systems in the region. For instance, as per the 2022 statistics published by the National Brain Tumor Society, approximately 88,970 people were expected to be diagnosed with a primary brain tumor in the United States in 2022. In addition, as per the same source, an estimated 4,170 new cases of childhood brain tumors and 12,072 new cases of adolescent and young adult brain tumors were expected to be diagnosed in 2022. Furthermore, according to AHA statistics, more than 130 million adults in the United States are expected to have some form of heart disease by June 2021. So, the high number of people with heart disease and brain tumors is likely to increase the demand for microneedle drug delivery technology, which is expected to help the market grow in the region.

Additionally, according to an article published by the Center for Health Protection, in December 2022, the rate of hospitalization for flu in the United States was 16.6 per 100,000 people between October 1, 2022, and November 26, 2022. Hence, the high number of flu cases in the population increases the demand for microneedles coated with whole, inactivated influenza viruses that deliver the antigen cargo through the tight stratum corneum skin barrier, causing protective immunity and driving the growth of the market.

Furthermore, the rising company's focus on adopting various strategic initiatives, such as collaboration, partnerships, agreements, and others, is expected to fuel market growth in the region over the forecast period. For instance, in December 2021, Wrinkles Schminkles launched self-dissolving microneedle patches with 1800 microneedles that use innovative technology to directly deliver active ingredients deep into the skin. The patch smooths out tiny lines and wrinkles by self-dissolving and releasing the active ingredients into the dermal layers of the skin. Also, PharmaTher and TSRL signed a co-development agreement in June 2021 to work together on making a microneedle array patch.

Thus, the studied market is expected to grow over the next few years because of things like the high number of people with chronic and infectious diseases and the growing number of company activities and new product launches.

Microneedle Drug Delivery Systems Industry Overview

The microneedle drug delivery systems market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies currently dominating the market are 3M Company, Becton, Dickinson and Company, Raphas Co. Ltd, Nanopass Technologies, Corium Inc., Nitto Denko Corporation, Zealand Pharma AS, nanoBioSciences LLC, Micropoint Technologies, LTS Lohmann Therapie-Systeme AG, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Diseases and Lifestyle-related Disorders
    • 4.2.2 Increasing Research on Painless Drug Delivery and Technological Advancement
    • 4.2.3 Increasing Demand for a Safer Substitute to Conventional Hypodermic Injections
  • 4.3 Market Restraints
    • 4.3.1 Limited Number of Approved Products and Complications/Risks Associated with Microneedles
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 Product Type
    • 5.1.1 Solid
    • 5.1.2 Hollow
    • 5.1.3 Coated
    • 5.1.4 Dissolvable
  • 5.2 Application
    • 5.2.1 Drug Delivery
    • 5.2.2 Vaccine Delivery
    • 5.2.3 Dermatology
    • 5.2.4 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Candela Corporation
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Raphas Co. Ltd.
    • 6.1.4 Nanopass Technologies
    • 6.1.5 Corium Inc.
    • 6.1.6 Nitto Denko Corporation
    • 6.1.7 Dermaroller GmbH
    • 6.1.8 nanoBioSciences LLC
    • 6.1.9 Micropoint Technologies
    • 6.1.10 LTS Lohmann Therapie-Systeme AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦